Review of the novelties presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (I);Revisión de las novedades presentadas en el XXVIII Congreso del Comité Europeo para el Tratamiento e Investigación en Esclerosis Múltiple (ECTRIMS) (I)

Revista de Neurologia

Volumn 57, Issue 5, 2013, Pages 217-229

  Fernández, Óscar ^a   Arnal García, Carmen ^b   Arroyo González, Rafael ^c   Brieva, Lluís ^d   Calles Hernández, M Carmen ^e   Casanova Estruch, Bonaventura ^f   Comabella, Manuel ^g   de las Heras, Virginia ^h   García Merino, Juan A ⁱ   Hernández Pérez, Miguel A ^j   Izquierdo, Guillermo ^k   Matas, Elisabet ^l   Meca Lallana, José E ^m   Mendibe Bilbao, María del Mar ⁿ   Muñoz García, Delicias ^o   Olascoaga, Javier ^p   Oreja Guevara, Celia ^c   Prieto, José M ^q   Ramió Torrentà, Lluís ^r   Rodríguez Antigüedad, Alfredo ^s   Saiz, Albert ^t   Téllez, Nieves ^u   Villar, Luisa M ^v   Tintoré, Mar ^g   more..

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d HOSPITAL ARNAU DE VILANOVA   (Spain)

^e HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^f HOSPITAL UNIVERSITARIO LA FE   (Spain)

^g HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^h HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

ⁱ HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^j HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^k HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^l HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^m HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

ⁿ HOSPITAL DE CRUCES   (Spain)

^o HOSPITAL XERAL CÍES   (Spain)

^p HOSPITAL DONOSTIA   (Spain)

^q HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^r HOSPITAL JOSEP TRUETA   (Spain)

^s HOSPITAL DE BASURTO   (Spain)

^t HOSPITAL CLÍNIC   (Spain)

^u HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^v HOSPITAL RAMÓN Y CAJAL   (Spain)

more..

Author keywords

Environment; Genes; Hormones; Inflammation; Multiple sclerosis; Neurodegeneration

Indexed keywords

DISEASE PREDISPOSITION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENVIRONMENTAL FACTOR; HUMAN; HYPOXIA; INCIDENCE; INFLAMMATION; MEDICAL RESEARCH; MULTIPLE SCLEROSIS; PATHOGENESIS; PREVALENCE; REVIEW; SEX DIFFERENCE;

ADULT; AGE OF ONSET; CELL ADHESION; CELL HYPOXIA; CHILD; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GONADAL STEROID HORMONES; HUMANS; INFLAMMATION; LACTATION; MACROPHAGE ACTIVATION; MALE; MITOCHONDRIA; MULTIPLE SCLEROSIS; NERVE DEGENERATION; OLIGODENDROGLIA; PREGNANCY; PREGNANCY COMPLICATIONS; RISK FACTORS; SMOKING; SODIUM CHANNELS; VITAMIN D;

EID: 84883442592     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.5705.2013270     Document Type: Review

References (78)

1. Imrell K, Greiner E, Hillert J, Masterman T. HLA-DRB115 and cerebrospinal-fluid-specific oligoclonal immunoglobulin G bands lower age at attainment of important disease milestones in multiple sclerosis. J Neuroimmunol 2009; 210: 128-30.
2. Link J, Kockum I, Lorentzen AR, Lie BA, Celius EG, Westerlind H, et al. Importance of human leukocyte antigen (HLA) class I and II alleles on the risk of multiple sclerosis. PLoS One 2012; 7: e36779.
3. Lundstrom W, Greiner E, Lundmark F, Westerlind H, Smestad C, Lorentzen AR, et al. No influence on disease progression of non-HLA susceptibility genes in MS. J Neuroimmunol 2011; 237: 98-100.
4. Duquette P, Pleines J, Girard M, Charest L, Senecal-Quevillon M, Masse C. The increased susceptibility of women to multiple sclerosis. Can J Neurol Sci 1992; 19: 466-71.
5. Kantarci OH, Hebrink DD, Schaefer-Klein J, Sun Y, Achenbach S, Atkinson EJ, et al. Interferon gamma allelic variants: sex-biased multiple sclerosis susceptibility and gene expression. Arch Neurol 2008; 65: 349-57.
6. Byun E, Caillier SJ, Montalban X, Villoslada P, Fernández O, Brassat D, et al. Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. Arch Neurol 2008; 65: 337-44.
7. Comabella M, Craig DW, Morcillo-Suárez C, Río J, Navarro A, Fernández M, et al. Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis. Arch Neurol 2009; 66: 972-8.
8. Gross R, Healy BC, Cepok S, Chitnis T, Khoury SJ, Hemmer B, et al. Population structure and HLA DRB1 1501 in the response of subjects with multiple sclerosis to first-line treatments. J Neuroimmunol 2011; 233: 168-74.
9. Selmi C. The X in sex: how autoimmune diseases revolve around sex chromosomes. Best Pract Res Clin Rheumatol 2008; 22: 913-22.
10. Spach KM, Blake M, Bunn JY, McElvany B, Noubade R, Blankenhorn EP, et al. Cutting edge: the Y chromosome controls the age-dependent experimental allergic encephalomyelitis sexual dimorphism in SJL/J mice. J Immunol 2009; 182: 1789-93.
11. Dunn SE, Bhat R, Straus DS, Sobel RA, Axtell R, Johnson A, et al. Peroxisome proliferator-activated receptor delta limits the expansion of pathogenic Th cells during central nervous system autoimmunity. J Exp Med 2010; 207: 1599-608.
12. Gold R. Gender differences in the immune system and response to immunotherapy. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
13. Voskuhl RR, Gold SM. Sex-related factors in multiple sclerosis susceptibility and progression. Nat Rev Neurol 2012; 8: 255-63.
14. Sicotte NL, Giesser BS, Tandon V, Klutch R, Steiner B, Drain AE, et al. Testosterone treatment in multiple sclerosis: a pilot study. Arch Neurol 2007; 64: 683-8.
15. Giatti S, D'Intino G, Maschi O, Pesaresi M, García-Segura LM, Calza L, et al. Acute experimental autoimmune encephalomyelitis induces sex dimorphic changes in neuroactive steroid levels. Neurochem Int 2010; 56: 118-27.
16. Kipp M, Beyer C. Impact of sex steroids on neuroinflammatory processes and experimental multiple sclerosis. Front Neuro-endocrinol 2009; 30: 188-200.
17. McCombe PA, Greer JM. Female reproductive issues in multiple sclerosis. Mult Scler 2013; 19: 392-402.
18. Ramagopalan SV, Valdar W, Criscuoli M, DeLuca GC, Dyment DA, Orton SM, et al. Age of puberty and the risk of multiple sclerosis: a population based study. Eur J Neurol 2009; 16: 342-7.
19. D'Hooghe MB, Haentjens P, Nagels G, D'Hooghe T, De Keyser J. Menarche, oral contraceptives, pregnancy and progression of disability in relapsing onset and progressive onset multiple sclerosis. J Neurol 2012; 259: 855-61.
20. Holmqvist P, Hammar M, Landtblom AM, Brynhildsen J. Symptoms of multiple sclerosis in women in relation to cyclical hormone changes. Eur J Contracept Reprod Health Care 2009; 14: 365-70.
21. Willer CJ, Sadovnick AD, Ebers GC. Microchimerism in autoimmunity and transplantation: potential relevance to multiple sclerosis. J Neuroimmunol 2002; 126: 126-33.
22. Ponsonby AL, Lucas RM, Van der Mei IA, Dear K, Valery PC, Pender MP, et al. Offspring number, pregnancy, and risk of a first clinical demyelinating event: the AusImmune Study. Neurology 2012; 78: 867-74.
23. Nielsen NM, Jorgensen KT, Stenager E, Jensen A, Pedersen BV, Hjalgrim H, et al. Reproductive history and risk of multiple sclerosis. Epidemiology 2011; 22: 546-52.
24. Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med 1998; 339: 285-91.
25. Amato M. Pregnancy. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
26. Vukusic S, Hutchinson M, Hours M, Moreau T, Cortinovis-Tourniaire P, Adeleine P, et al. Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain 2004; 127: 1353-60.
27. Vukusic S, El-Etr M, Ionescu I, Cotton F, Merle H, Cornu C, et al. The POPARTMUS French-Italian multicentric trial of Post Partum Progestin and Estriol in Multiple Sclerosis: final results. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
28. Achiron A, Kishner I, Dolev M, Stern Y, Dulitzky M, Schiff E, et al. Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis. J Neurol 2004; 251: 1133-7.
29. De Seze J, Chapelotte M, Delalande S, Ferriby D, Stojkovic T, Vermersch P. Intravenous corticosteroids in the postpartum period for reduction of acute exacerbations in multiple sclerosis. Mult Scler 2004; 10: 596-7.
30. Karp I, Manganas A, Sylvestre M, Roger E, Ho A, Duquette P. The impact of pregnancy on progression of relapsing-remitting multiple sclerosis. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
31. Hellwig K, Haghikia A, Rockhoff M, Gold R. Multiple sclerosis and pregnancy: experience from a nationwide database in Germany. Ther Adv Neurol Disord 2012; 5: 247-53.
32. Pakpoor J, Disanto G, Lacey MV, Hellwig K, Giovannoni G, Ramagopalan SV. Breastfeeding and multiple sclerosis relapses: a meta-analysis. J Neurol 2012; 259: 2246-8.
33. Bourre B, Marignier R, Zephir H, Papeix C, Brassat D, Castelnovo G, et al. Neuromyelitis optica and pregnancy. Neurology 2012; 78: 875-9.
34. Correale J, Farez MF, Ysrraelit MC. Increase in multiple sclerosis activity after assisted reproduction technology. Ann Neurol 2012; 72: 682-94.
35. Michel L, Foucher Y, Vukusic S, Confavreux C, De Seze J, Brassat D, et al. Increased risk of multiple sclerosis relapse after in vitro fertilisation. J Neurol Neurosurg Psychiatry 2012; 83: 796-802.
36. Waubant E. MS treatments during pregnancy. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
37. Cristiano L, Bozic C, Bloomgren G, Friend S, Liu Y. Preliminary evaluation of pregnancy outcomes from the Tysabri ® (natalizumab) Pregnancy Exposure Registry. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2013.
38. Geissbühler Y, Butzkueven H, Hernández-Díaz S, Hellwig G, Koren G, MacDonald T, et al. Pregnancy outcomes from fingolimod clinical trials and post-marketing experience and the need for a multinational Gilenya® (fingolimod) Pregnancy Exposure Registry in multiple sclerosis. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
39. Jilek S, Schluep M, Harari A, Canales M, Lysandropoulos A, Zekeridou A, et al. HLA-B7-restricted EBV-specific CD8+ T cells are dysregulated in multiple sclerosis. J Immunol 2012; 188: 4671-80.
40. Sundqvist E, Bergström T, Daialhosein H, Sundström P, Hillert J, Alfredsson L, et al. Cytomegalovirus seropositivity is associated with lower multiple sclerosis risk. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
41. Van der Mei IA, Ponsonby AL, Dwyer T, Blizzard L, Simmons R, Taylor BV, et al. Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study. BMJ 2003; 327: 316.
42. Munger KL, Zhang SM, O'Reilly E, Hernan MA, Olek MJ, Willett WC, et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 2004; 62: 60-5.
43. Smolders J, Hupperts R, Barkhof F, Grimaldi LM, Holmoy T, Killestein J, et al. Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: a phase II, multicenter, double-blind, randomized, placebo-controlled trial. J Neurol Sci 2011; 311: 44-9.
44. Ramagopalan S. From physico-chemical agents exposure to MS. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
45. Bjørnevik K, Riise T, Wesnes K, Granieri E, Casetta I, Drulovic J, et al. An age at exposure effect in the association between sun exposure and the risk of MS in Norway and Italy. The EnvIMS study. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
46. Koch-Henriksen N, Sorensen PS. Why does the north-south gradient of incidence of multiple sclerosis seem to have disappeared on the northern hemisphere? J Neurol Sci 2011; 311: 58-63.
47. Manouchehrinia A, Weston M, Constantinescu C. Smoking is a potentially modifiable risk factor for all causes of mortality in patients with multiple sclerosis. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
48. Kotzamani D, Panou T, Mastorodemos V, Tzagournissakis M, Nikolakaki H, Spanaki C, et al. Rising incidence of multiple sclerosis in females associated with urbanization. Neurology 2012; 78: 1728-35.
49. Comi G, Battaglia M, Bertolotto A, Del Sette M, Ghezzi A, Malferrari G, et al. Chronic cerebro-spinal venous insufficiency (CCSVI) and global venous haemodynamics in multiple sclerosis: the CoSMo study. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
50. Krupp LB, Banwell B, Tenembaum S. Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology 2007; 68 (Suppl 2): S7-12.
51. Renoux C, Vukusic S, Mikaeloff Y, Edan G, Clanet M, Dubois B, et al. Natural history of multiple sclerosis with childhood onset. N Engl J Med 2007; 356: 2603-13.
52. Chabas D, Castillo-Trivino T, Mowry EM, Strober JB, Glenn OA, Waubant E. Vanishing MS T2-bright lesions before puberty: a distinct MRI phenotype? Neurology 2008; 71: 1090-3.
53. Callen DJ, Shroff MM, Branson HM, Lotze T, Li DK, Stephens D, et al. MRI in the diagnosis of pediatric multiple sclerosis. Neurology 2009; 72: 961-7.
54. Mikaeloff Y, Adamsbaum C, Husson B, Vallee L, Ponsot G, Confavreux C, et al. MRI prognostic factors for relapse after acute CNS inflammatory demyelination in childhood. Brain 2004; 127: 1942-7.
55. Chabas D, Ness J, Belman A, Yeh EA, Kuntz N, Gorman MP, et al. Younger children with MS have a distinct CSF inflammatory profile at disease onset. Neurology 2010; 74: 399-405.
56. Ghezzi A, Pozzilli C, Moiola L, Brescia Morra V, Grimaldi L, Lus G, et al. Natalizumab in paediatric multiple sclerosis: long-term results of 55 cases. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
57. Kornek B. Natalizumab therapy in active paediatric multiple sclerosis. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
58. Banwell B, Bar-Or A, Giovannoni G, Dale RC, Tardieu M. Therapies for multiple sclerosis: considerations in the pediatric patient. Nat Rev Neurol 2011; 7: 109-22.
59. Zipp F. From focal inflammation to neurodegeneration. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
60. Mahad D. Neurons in MS. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
61. Kuhlmann T. Oligodendrocytes in MS. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
62. Masaki K, Suzuki S, Matsushita T, Matsuoka T, Suzuki M, Suenaga T, et al. Early disruption of astrocytic connexins in multiple sclerosis, Baló's disease and neuromyelitis optica. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
63. Wu C, Moore C, Leong S, Johnson T, Kennedy T, Séguéla P, et al. Dosing regimen impacts in vitro effects of FTY720 on human astrocyte proliferation, IL1b-induced Ca2+ mobilisation, and miRNA-155 expression. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
64. Merkler D, Boretius S, Stadelmann C, Ernsting T, Michaelis T, Frahm J, et al. Multicontrast MRI of remyelination in the central nervous system. NMR Biomed 2005; 18: 395-403.
65. Manrique-Hoyos N, Jurgens T, Gronborg M, Kreutzfeldt M, Schedensack M, Kuhlmann T, et al. Late motor decline after accomplished remyelination: impact for progressive multiple sclerosis. Ann Neurol 2012; 71: 227-44.
66. Lhuillier A, Chanal M, Androdias G, Reynolds R, Confavreux C, Nataf S. Periplaques form extensive lesions in multiple sclerosis spinal cords. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
67. Clarner T, Diederichs F, Berger K, Denecke B, Gan L, Van der Valk P, et al. Myelin debris regulates inflammatory responses in an experimental demyelination animal model and multiple sclerosis lesions. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
68. Clarner T, Diederichs F, Berger K, Denecke B, Gan L, Van der Valk P, et al. Myelin debris regulates inflammatory responses in an experimental demyelination animal model and multiple sclerosis lesions. Glia 2012; 60: 1468-80.
69. Schulz C, Gómez PE, Chorro L, Szabo-Rogers H, Cagnard N, Kierdorf K, et al. A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science 2012; 336: 86-90.
70. Ransohoff R. Microglia and monocytes: kith or kin? 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
71. Ransohoff RM. Microglia and monocytes: 'tis plain the twain meet in the brain. Nat Neurosci 2011; 14: 1098-100.
72. Lang S, Drouvelis P, Tafaj E, Bastian P, Sakmann B. Fast extraction of neuron morphologies from large-scale SBFSEM image stacks. J Comput Neurosci 2011; 31: 533-45.
73. Siffrin V, Gollan R, Birkenstock J, Paterka M, Zipp F. Preventing neurodegeneration in neuroinflammation-an in vivo two-photon imaging approach. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
74. Black JA. Sodium channels in MS. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
75. Black JA, Waxman SG. Sodium channels and microglial function. Exp Neurol 2012; 234: 302-15.
76. Shields SD, Cheng X, Gasser A, Saab CY, Tyrrell L, Eastman EM, et al. A channelopathy contributes to cerebellar dysfunction in a model of multiple sclerosis. Ann Neurol 2012; 71: 186-94.
77. Fernández O, Arnal-García C, Arroyo-González R, Brieva LL, Calles-Hernández MC, Casanova-Estruch B, et al. Revisión de las novedades presentadas en el XXVIII Congreso del Comité Europeo para el Tratamiento e Investigación en Esclerosis Múltiple (ECTRIMS) (II). Rev Neurol 2013 [in press].
78. Fernández O, Arnal-García C, Arroyo-González R, Brieva LL, Calles-Hernández MC, Casanova-Estruch B, et al. Revisión de las novedades presentadas en el XXVIII Congreso del Comité Europeo para el Tratamiento e Investigación en Esclerosis Múltiple (ECTRIMS) (III). Rev Neurol 2013 [in press].